Home > Oncology > ESMO 2021 > Breast Cancer > Postmenopausal breast cancer: extended letrozole reduces recurrence

Postmenopausal breast cancer: extended letrozole reduces recurrence

Presented By
Prof. Lucia Del Mastro, University of Genoa, Italy
ESMO 2021
Phase 3
In postmenopausal patients with breast cancer who received 2–3 years of tamoxifen, treating women with an extended 5-year treatment with the aromatase inhibitor letrozole significantly improved disease-free survival (DFS) compared with the standard approach of 2–3 years of letrozole. Prof. Lucia Del Mastro (University of Genoa, Italy) presented the results of a multicentre, open-label, randomised phase 3 trial (NCT01064635), which was simultaneously published in the Lancet Oncology [1,2]. Postmenopausal women with stage 1–3 histologically proven and operable invasive HR-positive breast cancer (n=2,056) were enrolled between 1 August 2005 and 24 October 2010 and randomly assigned to receive letrozole (2.5 mg once daily) for 2–3 years (n=1,030, as the control group), or for 5 years (n=1,026, as the “extended” group). The primary endpoint was invasive di...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on